Table 2.
(A) | HEALTHY OVARIAN TISSUE | NORMAL ADJACENT OVARIAN TISSUE | I | Ia | Ib | Ic | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Staining intensity | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 |
Cells only | 8 | 8 | 32 | 59 | 1 | 41 | 32 | |||||||||||||||||
Actin | 0 | 2 | 5 | 1 | 0 | 8 | 1 | 18 | 4 | 9 | 4 | 33 | 16 | 6 | 2 | 22 | 12 | 5 | 2 | 18 | 10 | 2 | ||
CA125 | 7 | 1 | 5 | 3 | 18 | 9 | 4 | 42 | 14 | 3 | 1 | 22 | 16 | 3 | 23 | 7 | 1 | |||||||
PASD1a + b | 5 | 2 | 8 | 29 | 3 | 58 | 2 | 39 | 1 | 1 | 32 | |||||||||||||
PASD1b | 6 | 1 | 2 | 5 | 1 | 25 | 7 | 47 | 12 | 37 | 4 | 29 | 3 |
(B) | II | IIb | IIc | III | IIIc | IV | SKIN CANCER | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Staining intensity | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 |
Cells only | 11 | 2 | 1 | 3 | 2 | 4 | 1 | |||||||||||||||||||||
Actin | 0 | 4 | 6 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 3 | 0 | 1 | 2 | 1 | 1 | ||||||||||||
CA125 | 6 | 4 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | ||||||||||||||||
PASD1a + b | 10 | 1 | 2 | 1 | 3 | 2 | 1 | 4 | 1 | |||||||||||||||||||
PASD1b | 11 | 1 | 1 | 1 | 3 | 3 | 4 | 1 |
(C) | CELLS ONLY | CA125 | PASD1b | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Staining score | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 |
Malignant tumour | 30 | 17 | 4 | 9 | 30 | ||||||||||
Hyperplasia | 23 | 1 | 11 | 11 | 23 | ||||||||||
Metastasis | |||||||||||||||
Abdominal cavity | 2 | 1 | 1 | 1 | |||||||||||
Fibrofatty tissue | 1 | 1 | 1 | ||||||||||||
Lymph node | 1 | 1 | 1 | ||||||||||||
Pelvic cavity | 1 | 1 | 1 | ||||||||||||
Ovary | 1 | 1 | 1 | ||||||||||||
Inflammation | 5 | 4 | 1 | 5 | |||||||||||
Normal endometrial tissue | 16 | 8 | 2 | 4 | 2 | 16 |
Notes: Expression of PASD1a and b in (A) healthy tissue, normal tissue adjacent to ovarian cancer cells and stage I ovarian cancer (B) stage II, III and IV ovarian cancer and (C) endometrial tissues were investigated. CA125 was used as an industry standard comparator. Staining intensity is indicated by the colour of the cells as follows 0–1 was considered to be negative staining, 2–4 was considered to be positive immunolabelling with 2 being moderate levels of protein, 3 high levels and 4 very high levels of protein detected. Actin was used as the positive control to confirm the immunostaining protocol was working and provide a staining intensity comparator and cells only provided a control for background staining with haematoxylin. Scoring was also carried out for healthy ovarian tissue and normal adjacent tissue. A small number of tissue cores were missing from the MTAs following immunolabelling and so data on these samples is absent from the table. Melanoma (skin cancer) tissue on each TMA was used as a positive control for PASD1 immunolabelling.